Thalidomide (drug) (DrugBank: Thalidomide)
20 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 1 |
16 | Crow-Fukase syndrome | 0 |
20 | Adrenoleukodystrophy | 0 |
28 | Systemic amyloidosis | 0 |
49 | Systemic lupus erythematosus | 0 |
51 | Scleroderma | 0 |
53 | Sjogren syndrome | 0 |
56 | Behcet disease | 0 |
65 | Primary immunodeficiency | 0 |
84 | Sarcoidosis | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
94 | Primary sclerosing cholangitis | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
227 | Osler disease | 0 |
271 | Ankylosing spondylitis | 0 |
280 | Huge arteriovenous malformation with cervicofacial or limb lesion | 0 |
298 | Hereditary pancreatitis | 0 |
300 | IgG4-related disease | 0 |
331 | Idiopathic multicentric castleman disease | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00231140 (ClinicalTrials.gov) | December 2005 | 30/9/2005 | Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS) | Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: Thalidomide (drug) | Charite University, Berlin, Germany | NULL | Terminated | 25 Years | 80 Years | Both | 40 | Phase 2 | Germany |